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Summary.-Cytotoxic antibodies to antigens specific for leukaemic myeloblasts
have been sought in the serum of patients with acute myeloblastic leukaemia treated
by immunotherapy with irradiated allogeneic myeloblasts and BCG. Assays of
complement- and K-cell-mediated activity were used. Cytotoxicity to allogeneic
myeloblasts was detected in both assays.
When sera from 15 patients, taken at various times during immunotherapy, were
systematically tested against apanelof5myeloblasts,thefollowingpatterns emerged:
1. No antibody was cytotoxic against all myeloblasts of the panel in either the
K-cell or complement-dependent assay. However, all myeloblasts of the panel were
lysed by a number of sera.
2. Cytotoxic antibody was detected as often against a panel of lymphocytes from
healthy donors as against the panel of allogeneic myeloblasts.
3. Fresh and cryopreserved myeloblasts were equally susceptible to lysis in both
assays.
4. Experiments failed to demonstrate any deterioration of cytotoxic antibody on
storage.
5. The number of K-cell-revealed cytotoxic antisera increased with length of
immunotherapy. This pattern was not apparent for antibodies revealed by com-
plement.
6. No instance of cytotoxicity in either assay was seen when serum was tested
against 12 autologous myeloblasts. It is considered that cytotoxic antibody detected
with allogeneic myeloblasts is probably directed against HLA antigens common to
immunizing and test target myeloblasts and target lymphocytes.
CHEMOTHERAPY and supportive treat-
ment in acute myeloblastic leukaemia
(AML) has improved to the extent of
achieving complete remission in over
half the patients in a number of series
(Spiers, 1972). However, the length of
remissions is disappointingly short and,
while halfoffirst remissions may exceed a
year, only a handful of patients are alive
3 years after presentation. This situation
has provided a strong impetus to find
improved methods of sustaining remission
in this disease. Immunotherapy is among
the approaches tried, and some encour-
aging results have been reported (Powles
et al., 1973; Gutterman et at., 1974;
Vogler and Chan, 1974). The data from
the St Bartholomew's Hospital study
(Powles et at., 1973) are of particular
interest, for this trial included concurrent
controls treated with chemotherapy. The
immunotherapy patients received the
same chemotherapy, but were also given
109 allogeneic irradiated cryopreserved
leukaemic myeloblasts and live BCG
weekly after achieving remission.
One of the rationales for including
allogeneic myeloblasts in immunotherapy
is that these might share antigens with the
patients' own leukaemic cells. However,
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it should be stressed that the existence of
common tumour-specific antigens in acute
myeloblastic leukaemia has not yet been
proved, despite considerable work on this
topic. Autologous myeloblasts have been
showntoproducedelayed-hypersensitivity-
type skin responses at some time in the
course of the disease in most patients
(Baker et al., ].974b), and can also stimu-
late blastogenesis of autologous lympho-
cytes (Powles et al., 1971). Although
these data are consistent with the pre-
sence on the myeloblast of an antigen
foreign to the autologous host, these
studies do not demonstrate that the
antigens on different myeloblasts are
similar.
Various attempts have been made to
produce a xenogeneic serum which will
recognize myeloblastic-leukaemia-specific
antigen. Baker, Ramachandar and Taub
(1974a) in mice, and Mann, Halterman and
Leventhal (1974) in rabbits, have pro-
duced sera which they regarded as
probably myeloblast-specific. Seigler et
al. (1975), working with chimpanzees,
have not been able to produce sera
reacting with all myeloblasts, and suggest
that these more closely related animals
may be able to recognize differences in the
surface structure of human leukaemic
myeloblasts to which lower animals are
" blind ". They have produced antisera
which react with groups of myeloblasts,
though not with all. All these studies
have used absorption with normal human
tissue to produce sera thought to be more
reactive against myeloblasts than normal
tissues, but critical appraisal ofthese data
leaves some doubt as to whether they
conclusively demonstrate tumour-specific
antigens.
Hersey et al. (1973) previously de-
scribed a high incidence of antibody
which was cytotoxic against allogeneic
myeloblasts, in AML patients receiving
immunotherapy. These authors pointed
out that this activity could have been
directed against normal transplantation
antigens. This study seeks to assess the
specificity of such antibodies in sera from
patients undergoing immunotherapy in
the 6th Medical Research Council trial of
treatmentin acutemyeloblasticleukaemia.
PATIENTS
All material studied was from patients
in the Medical Research Council's 6th trial of
therapy in AML. The treatment protocol
was essentially that used in the St Bartholo-
mew's Hospital 3rd trial (Powles et al., 1973).
After induction of remission, patients were
given one further 5-day course of chemo-
therapy followed by weekly injections of 109
irradiated allogeneic cryopreserved myelo-
blasts in divided doses in 3 limbs subcutane-
ously and intradermally. Live BCG (Glaxo)
was inoculated into the fourth limb by Heaf
technique. Each limb was used for the
BCG administration in rotation. Mainten-
ance chemotherapy was given for 5 days
during each 4th week for the first 12 months
ofremission.
METHODS
(i) Target cells
The leukaemic myeloblasts used in this
study were collected from patients entered in
the 6th MRC trial who had high peripheral
white cell counts at presentation. In a few
cases, the myeloblasts were collected using a
continuous-flow cell separator (International
Business Machines) at the Royal Marsden
Hospital or Manchester Royal Infirmary.
The blood was collected into acid citrate
dextrose and allowed to sediment at 1 g for
1-2 h. The supernatant leucocyte-rich
plasma above the red cells was collected and
centrifuged. The cell residue was resus-
pended in autologous plasma or Hepes-
buffered Eagle's basal medium (BME) with
10% foetal bovine serum (FBS). After
addition of 10% dimethyl sulphoxide the
cells were frozen at -1°C per minute to
about - 60°C and then stored over liquid N2.
The myeloblasts used for the major part
of this work were chosen from those in store
at Oxford, because of their availability in
suitable numbers, viability and favourable
labelling characteristics. None of the panel
myeloblasts were derived from, or had been
used for immunization of any of the patients
whose sera were tested. Cytocentrifuge pre-
parations were made of aliquots of all
samples used, or from samples from the same
batch. In all cases, at least 90% ofthe cells
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in the preparations were judged on morpho-
logical grounds to be myeloblasts: the
remainder were lymphocytes. The myelo-
blasts were thawed rapidly and diluted drop
by drop over about 10 min with 10% FBS in
saline at 30°C. After centrifugation, approxi-
mately 2-3 x 107 myeloblasts were sus-
pended in 0 5 ml BME + FBS with 100 ,uCi
51Cr-chromate (Radiochemical Centre, Amer-
sham) and placed in a 30-ml universal
container. After incubation at 37°C for 2 h,
20 ml BME was added and 1P5 ml FBS care-
fully layered under the suspension. After
centrifugation, the supernatant was removed
and the myeloblasts resuspended at a con-
centration to give approximately 2 x 104
cells per well. In the labelling conditions
used by us the incorporation ofsodium [51Cr]
chromate by myeloblasts is somewhat greater
than that by lymphocytes (MacLennan, Gale
and Wood, 1975). It can therefore be
assumed that well over 90% of label in these
preparations was in myeloblasts.
Lymphocytes to be used as targets were
separated from heparinized blood of normal
volunteers by Ficoll-Triosil gradient. After
2 washes in BME the labelling procedure
used for myeloblasts was followed.
(ii) Test sera
Sera from patients receiving immuno-
therapy were collected from fresh, defibri-
nated blood and stored at -12°C until used.
Dilutions of 1/5, 1/20, 1/80, 1/320 and 1/1280
were used for complement-induced lysis.
Dilutions of 1/10, 1/50, 1/250, 1/1250 and 1/a
were used for assays of antibody-induced
lymphocyte-dependent cytotoxicity (K-cell-
dependent cytotoxicity or KDC). Two rat
sera known to have cytotoxic activity against
most myeloblasts were included in each assay
as a positive control. They were prepared by
pooling the sera of 3 rats, bled out 14 days
after i.p. injection of 5 x 107 human leukae-
mic myeloblasts.
(iii) Cytotoxic mediators
(a) Complement.-Fresh normal human
serum was frozen in liquid N2. Aliquots of
this were thawed for use as a complement
source. More than one pool was used but
all had good lytic activity against myelo-
blasts sensitized with positive control sera.
It was used in a final concentration of 20%.
(b) Lymphocytes (K cells).-For KDC
assays, lymphocytes were collected from
defibrinated normal human blood by gelatine
sedimentation. After centrifugation and one
wash in BME, the lymphocytes were resus-
pended and used at 3.5 x 105/well. Several
normal volunteers participated but only one
donor was involved in testing each myelo-
blast against the whole batch of sera.
(iv) Test procedure
All experiments were carried out in
sterile Biocult 250-,ul round-bottomed-well
microplates with 96 wells. All experiments
were carried out in duplicate, with a final
volume of200 ,tl per well. The basic medium
used was BME, supplemented with glutamine,
non-essential aminoacids and penicillin and
streptomycin. FBS was not added except
at the stage of labelling. As far as possible,
the medium was used at 37°C at all times.
Labelled target cells, test serum and
mediators were mixed in the concentration
and volumes indicated above and incubated
at 37°C. Complement assays were incubated
for 2- h and KDC assays for 6 h. After
incubation the plates were centrifuged at
100 g for 5 min and 150 ,ul of supernatant
was pipetted off and retained for counting.
To measure total 51Cr per well, 4 aliquots of
the target-cell mixture containing 2 x 104
cells were retained for separate counting.
Gamma emission ofthe samples was counted,
using a Wallac automatic well scintillation
counter. The percentage chromium release
(CR) was calculated by the formula:
CR- (133 x S -background) x 100 (T -background)
where
S = ct/s of supernatant.
T = total well ct/s (mean counts
of aliquots of myeloblast
mixture).
background= background irradiation in
ct/s (taken to be a constant,
0 9 ct/s).
RESULTS
1. Assessment of cytotoxicity
Results were graded as being positive,
possibly positive or negative for cyto-
toxicity. The criteria for this assessment
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FIG. 1. Assessment of cytotoxicty. The fig-
ure shows the grading of the cytotoxicity of
3 sera from one patient for one myeloblast
in the K-cell-dependent cytotoxicity assay.
The shaded square indicates grading as
definitely positive; the semi-shaded square
indicates grading as possibly positive and
the open square grading as negative. The
same grading method is used for comple-
ment-dependent cytotoxicity.
are illustrated in Fig. 1, where the cyto-
toxicity ofa positive, possible and negative
serum from one patient against one
myeloblast in the KDC assay is illustrated.
A rise of at least 100% above baseline CR
in the first titre and at least 500 in the
second titre was regarded as positive
evidence of cytotoxicity. A rise of5% to
15% above baseline CR produced by only
one titre of a serum was regarded as
possible evidence of cytotoxicity. The
target myeloblasts used for panel experi-
ments had a baseline release between 10
and 3500 and positive control sera pro-
duced maximum releases of between 80
and 9500 with complement. Some auto-
logous myeloblasts were less satisfactory
targets, but 11/12 showed definite CR as
defined above, with control sera and
complement.
Baselines were usually stable and
reliable in the KDC assays, perhaps due to
the feeder effect of added cells. They
were less stable in the complement assays,
making interpretation of the results in
these assays rather more difficult. Some
false positive readings may have resulted,
but it is unlikely that a true positive
result could have been misread asnegative.
2. Activity of sera against a panel of
myeloblasts
Sera were selected from patients who
had had at least 12 weeks of immuno-
therapy; sera of 13 patients were studied
k for complement-mediated cytotoxicity and
of 15 patients for activity in the KDC
assay. Sera taken at 12, 24, 48, 72 and 96
weeks after starting immunotherapy were
tested where available, provided the
patient was still on immunotherapy. All
patients were in first remission through-
out the period ofstudy, except Patient H.,
who had a short relapse followed by a
second remission between the taking of
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FIG. 2. The activityoftheseraagainstapanel
of myeloblasts in the complement-depend-
ent assay. Each block of squares represents
the activity of one serum against the 5
myeloblasts which are shown in fixed order.
For grading code see Fig. 1.
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FIG. 3.-The activity of the sera against a
panel of myeloblasts in the K-cell-depen-
dent cytotoxicity assay. Each block of
squares represents the activity of one serum
against the 5 myeloblasts which are shown
in fixed order. For grading code see Fig. 1.
the second and third sera. Immuno-
therapy was continued into the second
relapse.
Each serum was tested against 5
myeloblasts by eaich of the 2 assays; the
results of these tests are shown in Figs. 2
and 3. The first 4 myeloblasts of the
panels used in the 2 types ofassay are the
same, allowing comparison of the results
of the 2 panels.
If cytotoxic antibody against a myelo-
blast-specific antigen were being produced
regularly in response to the form of
immunotherapy under study, it would be
expected that several sera cytotoxic to all
of the panels of myeloblasts would have
been detected. In fact, in no case was a
serum able todamage allofthe myeloblasts
in a panel, and few could produce cyto-
toxicity to 4 myeloblasts. Comparison of
the pattern of occurrence of antibody-
inducing complement-mediated and KDC
lysis shows a tendency for complement
lytic capacity to occur both early and late
in the course of immunotherapy and not
necessarily to persist once present. In
contrast, KDC lytic capacity occurs with
increasing frequency with increased dur-
ation of treatment, and once present is
more constant. When the number of
positive responses produced by a serum is
related to the number of different myelo-
blasts which had been used to immunize
the donor of the serum, a significant
correlation is seen for the KDC assay, but
not for the complement lytic assay (Fig.4).
As a single myeloblast was used for
* KDC assay
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FIG. 4.-The number of positive or possible
positive results for each serum tested is
related to the number of myeloblasts from
individual donors which has been used to
immunize the patient at the time when the
serum was taken. A positive correlation is
seen between the number of donors and
incidence of cytotoxicity in the K-cell-
dependent assay. The correlation is not
significant in the case of the complement-
dependent cytotoxicity test. The signifi-
cance was calculated by non-parametric
correlation coefficient between the number
of positive observations and number of
myeloblasts used to immunize.
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immunization of each patient until sup-
plies were exhausted and then immuni-
zation with a second or third myeloblast
was started, the effect of increased
numbers of immunizing myeloblasts can-
not be separated from the effect ofgreater
duration of immunotherapy.
There was little or no correlation
between positive results in the 2 assays
for individual sera, suggesting that these
assays were measuring a partially or
wholly different range ofantibodies and/or
antigens.
3. The effect of cryopreservation of myelo-
blasts on sensitivity to antibody-induced
Iysis
A comparison was made ofthe pattern
of cytotoxicity produced against 3 myelo-
blasts studied in the fresh and frozen
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FIG. 5. The activity of 3 sera against a
myeloblast comparing the results using a
fresh (unbroken line) or cryopreserved
(broken line) target cell.
state. The KDC of 34 sera for one
myeloblast was compared using fresh and
frozen myeloblasts as targets. An identi-
cal pattern of positive, possible positive
and negative cytotoxic results was seen
in both cases. Fig. 5 shows a comparison
of the cytotoxicity of 3 active sera for
fresh and frozen myeloblasts. Allowing
for a lower baseline release from the fresh
myeloblasts, the pattern is similar in both
situations. In one case where there was a
five-fold difference in titre, the frozen
myeloblast was more sensitive. The cyto-
toxicity of 7 selected sera was compared
for fresh and frozen myeloblasts ofanother
2 patients. Again, no difference in sus-
ceptibility to cytotoxicity was seen, apart
from an increased baseline release from
frozen cells. It therefore seems unlikely
that the use of frozen cells has prevented
recognition of cytotoxicity in this system.
The properties of antibody and myelo-
blasts appeared to be retained for periods
of several months. This was shown by
repeating assays with the same serum
sample and batch of myeloblasts at
intervals ofone year.
4. Activity of sera against a panel of blood
lymphocytes from healthy donors
To test the specificity ofthe activity of
these sera, 7 sera cytotoxic to myelo-
blasts were selected, and tested for KDC
activity against the peripheral blood
lymphocytes of 5 healthy volunteers. In
Fig. 6 the cytotoxic activity observed is
compared with that of the same sera for
myeloblasts. The sera proved to be
equally active against lymphocytes and
myeloblasts, showing that there was con-
siderable activity against normal allo-
geneic antigens. This activity might
overlap with most or possibly all of the
antibody-induced cytotoxicity against
allogeneic leukaemic myeloblasts. The
remaining experiments were designed to
see ifany ofthe cytotoxic activity in these
sera was myeloblast specific.
5. Effect of sera on autologous myeloblasts
Sufficient cryopreserved myeloblasts
were available from 12 patients to allow
testing of the effect of sera on autologous
myeloblasts. Sera taken before and at
intervals during immunotherapy were
tested for cytotoxicity in both complement
and KDC assays. No instance of cyto-
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FIG. 6. The cytotoxicity of 7 selected sera
for apanel ofmyeloblasts (lefthand column)
compared with the activity of the same sera
for a panel of lymphocytes from healthy
volunteers (right hand) column). Each set
of 5 squares represents the cytotoxicity of
one serum for the panel of targets. For
grading code see Fig. 1. The totals in each
category of cytotoxicity are given below.
The incidence ofcytotoxicity for both types
of target cell is very similar.
toxicity against an autologous mveloblast
was found, although many ofthe sera were
active against allogeneic myeloblasts.
Postive controls were included in every
experiment.
DISCUSSION
The clinical results of immunotherapy
have generally been disappointing (Currie,
1972). An exception to this discouraging
picture was the report by Powles et al.
(1973) of the St Bartholomew's trial of
immunotherapy for AML. The present
trial adhered to the treatment protocol
used in the 3rd St Bartholomew's trial.
Hersey et al. (1973) had reported cyto-
toxic activity to numbers of allogeneic
myeloblasts in the serum of similarly
treated immunotherapy patients, and the
studies reported here concentrated on
efforts to detect specific antimyeloblast
activity mediated by antibody in patients
treated by immunotherapy.
Serum of patients treated with this
type of immunotherapy contain anti-
bodies capable of inducing both comple-
ment- and K-cell-dependent lysis of allo-
geneic myeloblasts. Complement-depen-
dent antibody occurs both early and late
in the course of immunotherapy, whereas
KDC antibody appears with increased
frequency with increased duration of
immunotherapy and number of immuniz-
ing myeloblasts used. Some of the dif-
ference in this pattern of occurrence may
relate to the fact that complement-
dependent cytotoxicity can be induced by
both IgM and IgG, while KDC is generally
only induced by IgG.
The detected activity did not appear
to be directed against an antigen univer-
sally present on, and specific to myelo-
blasts. No serum was active against all
of the panel of 5 myeloblasts used, a
similar incidence of cytotoxicity of the
same sera to normal peripheral blood
lymphocytes was seen, and activity against
autologous myeloblasts was not seen.
What then is the nature of the ob-
served activity? Klouda et al. (1975) have
demonstrated cytotoxicity to lympho-
cytes in the serum of immunotherapy
patients. These antibodies appeared to
be directed against HLA antigens.
Hersey et al. (1973) recognized that the
activity they detected might be of this
type. The findings presented here would
be compatible with the hypothesis that
the cytotoxicity observed was directed at
HLA antigens present on the immunizing
and " panel " myeloblasts and on the
normal lymphocytes used as targets. It
has been suggested that under certain
circumstances allogeneic antigens may
appear on tumour cells, which are
not normally present on the cells of the
tumour's host (Garrido, Schirrmacher and
Festenstein, 1976). This has been used as
an explanation of successful protection
against tumour growth in some animal
systems, by immunization with normal
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allogeneic tissue (Invernizzi and Parmiani,
1975). This work does not suggest that
immunotherapy used here has induced
antibody to HLA antigens on autologous
tumour cells.
The frequent finding of non-tumour-
specific cytotoxicity against allogeneic
myeloblasts emphasizes the need for
cautious interpretation of the results of
tests for tumour-specific cytotoxicity,
when allogeneic tumour cells or cell
culture lines are used as targets.
The work described here is limited, in
that it could only have demonstrated a
tumour-specific antigen capable of initiat-
ing the production of an antibody which
caninducecomplement-orK-cell-mediated
cytotoxicity. It cannot exclude the pre-
sence of tumour-specific antigens, on
myeloblasts, which under the conditions of
immunotherapy used do not induce cyto-
toxic antibody, but could be detected by
an alternative method such as indirect
immunofluorescence.
The failure to demonstrate cytotoxic
antibody which is reported here is con-
sistent with the clinical result of the trial
in which the patients studied were entered.
Present analysis shows no benefit in
immunotherapy patients over those
maintained by chemotherapy alone.
An interim report on this trial is being
prepared.
We are grateful to Drs S. Callender and
P. Emerson for allowing us to study their
patients and Drs R. Powles and J. Russel
for preparing myeloblasts from some of
our patients.
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